Form 8-K - Current report:
SEC Accession No. 0001104659-23-001861
Filing Date
2023-01-06
Accepted
2023-01-06 16:16:22
Documents
13
Period of Report
2023-01-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm231753d1_8k.htm   iXBRL 8-K 29067
  Complete submission text file 0001104659-23-001861.txt   248717

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cycc-20230104.xsd EX-101.SCH 3271
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cycc-20230104_def.xml EX-101.DEF 27200
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cycc-20230104_lab.xml EX-101.LAB 36811
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cycc-20230104_pre.xml EX-101.PRE 25822
7 EXTRACTED XBRL INSTANCE DOCUMENT tm231753d1_8k_htm.xml XML 5205
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 23515275
SIC: 2834 Pharmaceutical Preparations